Electrocardiography

Electrocardiograms (ECG) are a primary cardiac diagnostic test that measures the electrical activity in heart to identify overall cardiac function, arrhythmias and areas of ischemia and infarct. Standard 12-lead ECG breaks the 3D structure of the heart into 12 zones, each showing the electrical activity in that specific area of the heart. This narrows down areas where there are issues with coronary artery disease or electrophysiology issues. Many ambulatory heart monitors and consumer-grade ECG monitors use fewer leads so are less specific as to cardiac conditions or location of abnormal heart rhythms, but can show an issue that requires further diagnostic testing or treatment.

Thumbnail

HeartBeam raising $10M for FDA-cleared health tech with public offering

The FDA recently cleared the company's cable-free, credit card-sized heart monitor that produces 12-lead ECGs.

AI cardiology heart artificial intelligence deep learning

New AI model uses ECG images to evaluate heart failure risk

The advanced algorithm only needs an image or photograph of a 12-lead ECG to make its assessment. 

Medtronic's PulseSelect Pulse Field Ablation (PFA) System

Medtronic heart rhythm technologies on full display at AF Symposium 2025

Cardiologists shared updated data on Medtronic's ICM and PFA offerings during AF Symposium 2025 in Boston. 

FDA has now cleared more than 1,000 AI models, including many in cardiology

Cardiology is the medical speciality with the second most FDA clearances overall. 

HeartBeam, a California-based healthcare technology company, has received U.S. Food and Drug Administration (FDA) clearance for its cable-free, credit card-sized heart monitor that produces 12-lead electrocardiograms (ECGs).

FDA clears credit card-sized heart monitor

The new device was designed to help patients evaluate their own heart health in real time.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

AI-powered ECG screening a cost-effective way to ID heart failure patients

The technique was especially cost-effective in outpatient settings, according to a new study of more than 22,000 patients.

eko health digital stethoscope artificial intelligence

Eko Health’s AI platform for digital stethoscopes granted new CPT code

The Sensora platform, which includes multiple FDA-approved algorithms, has a new Category III CPT code.

artificial intelligence in cardiology

FDA grants AI-powered ECG screening tool for aortic stenosis its breakthrough device designation

The FDA clearly sees significant potential in this new screening software from New York-based AccurKardia.

Around the web

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.